Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Cisplatin + Gemcitabine as first-line therapy in advanced non-small cell lung cancer
2006-000537-35Phase 2Completed
- Sponsor
- Portuguese Lung Cancer Study Group
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Portuguese Lung Cancer Study Group. Primary endpoint: Overall Response Rate. Started May 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-000537-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000537-35.